Edgar Lomax Co Trimmed United Technologies (UTX) Holding; Vtv Therapeutics Class A (VTVT) Shorts Up By 8.63%

December 6, 2017 - By Louis Casey

Vtv Therapeutics Class A (NASDAQ:VTVT) had an increase of 8.63% in short interest. VTVT’s SI was 168,600 shares in December as released by FINRA. Its up 8.63% from 155,200 shares previously. With 41,800 avg volume, 4 days are for Vtv Therapeutics Class A (NASDAQ:VTVT)’s short sellers to cover VTVT’s short positions. The SI to Vtv Therapeutics Class A’s float is 2.39%. The stock increased 4.87% or $0.19 during the last trading session, reaching $4.09. About 8,256 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 0.20% since December 6, 2016 and is downtrending. It has underperformed by 16.90% the S&P500.

Edgar Lomax Co decreased United Technologies (UTX) stake by 2.82% reported in 2017Q2 SEC filing. Edgar Lomax Co sold 3,800 shares as United Technologies (UTX)’s stock rose 8.03%. The Edgar Lomax Co holds 131,154 shares with $16.02 million value, down from 134,954 last quarter. United Technologies now has $96.43B valuation. The stock increased 0.38% or $0.46 during the last trading session, reaching $120.75. About 147,026 shares traded. United Technologies Corporation (NYSE:UTX) has risen 22.99% since December 6, 2016 and is uptrending. It has outperformed by 6.29% the S&P500.

Among 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. vTv Therapeutics Inc had 3 analyst reports since August 24, 2015 according to SRatingsIntel. The company was initiated on Monday, August 24 by Piper Jaffray. The firm earned “Buy” rating on Friday, September 4 by Canaccord Genuity. The rating was initiated by Stifel Nicolaus on Monday, August 24 with “Buy”.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $134.20 million. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

Among 21 analysts covering United Technologies Corporation (NYSE:UTX), 7 have Buy rating, 0 Sell and 14 Hold. Therefore 33% are positive. United Technologies Corporation had 67 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, May 2, the company rating was downgraded by Goldman Sachs. The rating was downgraded by Argus Research on Thursday, January 26 to “Hold”. RBC Capital Markets maintained the stock with “Hold” rating in Friday, June 2 report. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, May 3. Jefferies maintained United Technologies Corporation (NYSE:UTX) rating on Monday, August 28. Jefferies has “Buy” rating and $139.0 target. The rating was downgraded by Barclays Capital to “Equal Weight” on Monday, August 31. Deutsche Bank maintained it with “Hold” rating and $112 target in Monday, December 5 report. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Tuesday, October 13 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, January 28. The firm has “Hold” rating given on Tuesday, August 25 by Deutsche Bank.

Analysts await United Technologies Corporation (NYSE:UTX) to report earnings on January, 24. They expect $1.56 earnings per share, 0.00% or $0.00 from last year’s $1.56 per share. UTX’s profit will be $1.25 billion for 19.35 P/E if the $1.56 EPS becomes a reality. After $1.73 actual earnings per share reported by United Technologies Corporation for the previous quarter, Wall Street now forecasts -9.83% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com